HomeAI · summaries
Storia in 6 fonti
Trodelvy earns FDA approval as first-line treatment for triple-negative breast cancer
The FDA has approved sacituzumab govitecan-hziy as first-line therapy for adults with unresectable locally advanced or metastatic triple-negative breast cancer across PD-L1 status. Sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences) — a TROP2-directed antibody-drug conjugate — received approval as a single agent for patients who are not eligible for PD-1 or PD-L1 inhibitors, and in
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
FDA backs Gilead’s Trodelvy for first-line, triple-negative breast cancer
FDA grants Gilead two first-line approvals for Trodelvy in triple-negative breast cancer, broadening its reach beyond Datroway's narrower indication.
- ·
fiercepharma.com
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
The game is on for TROP2 antibody-drug conjugates in first-line triple-negative breast cancer. | Less than a month after an approval for Daiichi Sankyo and AstraZeneca’s Datroway…
